

248 ROUTE 25A

EAST SETAUKET

City

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.

OMB APPROVAL
OMB Number: 3235-0076
Expires: August 31, 2015
Estimated Average burden hours per response: 4.0

1. Issuer's Identity			
CIK (Filer ID Number) P	revious Name(s)	☐ None	Entity Type
0001335105	SRKP 7 INC		© Corporation
Name of Issuer			C Limited Partnership
LIXTE BIOTECHNOLOGY HOLDINGS, INC.			C Limited Liability Company
Jurisdiction of Incorporation/Organization			C General Partnership
DELAWARE			C Business Trust
Year of Incorporation/Organization			C Other
© Over Five Years Ago			
Within Last Five Years (Specify Year)			
O Yet to Be Formed			
2. Principal Place of Bus	siness and (	Contact Info	rmation
Name of Issuer			
LIXTE BIOTECHNOLOGY HOLDIN	NGS, INC.		
Street Address 1		Street Address 2	

NO. 2

ZIP/Postal Code


11733

Phone No. of Issuer

(631) 880-2097

State/Province/Country

NEW YORK



Relationship:	Executive Officer Director Promoter
Clarification of Respons	se (if Necessary)
Last Name	First Name Middle Name
Forman	Stephen
Street Address 1	Street Address 2
248 Route 25A, No. 1	2
City	State/Province/Country ZIP/Postal Code
East Setauket	NEW YORK 11733
Relationship:	Executive Officer Director Promoter
Clarification of Respons	se (if Necessary)
Last Name	First Name Middle Name
Yen	Yun
Street Address 1	Street Address 2
248 Route 25A, No. 1	2
City	State/Province/Country ZIP/Postal Code
East Setauket	NEW YORK 11733
Relationship:	Executive Officer Director Promoter
Clarification of Respons	se (if Necessary)
Y (N)	TI AN
Last Name	First Name Middle Name
Но	Winson (Sze Chun)
Street Address 1	Street Address 2
248 Route 25A, No. 1	
City	State/Province/Country ZIP/Postal Code
East Setauket	
Relationship:	Executive Officer Director Promoter
Clarification of Respons	se (if Necessary)

# 4. Industry Group

C Agriculture	Health Care C Retailing	
Banking & Financial Services		
C Commercial Banking	C Hagnitals & Physicians	
C Insurance	C Pharmaceuticals	
C Investing	C Other Health Care	
C Investment Banking	C Telecommunications	
Pooled Investment Fund	C Other Technology	
Other Banking & Financial	Travel	
C Services	Manufacturing C Airlines & Airports	
C Business Services	Real Estate C Lodging & Conventions	
Energy C Coal Mining	C Commercial C Tourism & Travel Services C Construction	
C Electric Utilities	C Other Travel	
C Energy Conservation	C Residential	
C Environmental Services	C Other Real Estate	
Oil & Gas		
C Other Energy		
5. Issuer Size		
Revenue Range	Aggregate Net Asset Value Range	
C No Revenues	No Aggregate Net Asset Value	
C \$1 - \$1,000,000	\$1 - \$5,000,000	
C \$1,000,001 - \$5,000,000	C \$5,000,001 - \$25,000,000	
© \$5,000,001 - \$25,000,000	C \$25,000,001 - \$50,000,000	
C \$25,000,001 - \$100,000,000	C \$50,000,001 - \$100,000,000	
Over \$100,000,000	Over \$100,000,000	
© Decline to Disclose	C Decline to Disclose	
C Not Applicable	C Not Applicable	
A. A	A(07)) I.I.	
6. Federal Exemption(s) a apply)	and Exclusion(s) Claimed (select all that	
apply) Rule 504(b)(1) (not (i), (ii)		
apply)    Rule 504(b)(1) (not (i), (ii)   or (iii))	Rule 505	
apply)    Rule 504(b)(1) (not (i), (ii)	Rule 505  Rule 506(b)	
Rule 504(b)(1) (not (i), (ii)   or (iii))     Rule 504 (b)(1)(i)     Rule 504 (b)(1)(ii)	Rule 505  Rule 506(b)  Rule 506(c)	
apply)    Rule 504(b)(1) (not (i), (ii)	Rule 505  Rule 506(b)  Rule 506(c)  Securities Act Section 4(a)(5)	
Rule 504(b)(1) (not (i), (ii)   or (iii))     Rule 504 (b)(1)(i)     Rule 504 (b)(1)(ii)	Rule 505  Rule 506(b)  Rule 506(c)	
Rule 504(b)(1) (not (i), (ii)   or (iii))     Rule 504 (b)(1)(i)     Rule 504 (b)(1)(ii)	Rule 505  Rule 506(b)  Rule 506(c)  Securities Act Section 4(a)(5)	
Rule 504(b)(1) (not (i), (ii)   or (iii))     Rule 504 (b)(1)(i)     Rule 504 (b)(1)(ii)     Rule 504 (b)(1)(iii)     Rule 504 (b)(1)(iiii)     Rule 504 (b)(1)(iiii)     Rule 504 (b)(1)(iiii)     Rule 504 (b)(1)(iiii)     Rule 504 (b)(1)(iiiii)     Rule 504 (b)(1)(iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii	Rule 505  Rule 506(b)  Rule 506(c)  Securities Act Section 4(a)(5)	
Rule 504(b)(1) (not (i), (ii)   or (iii))     Rule 504 (b)(1)(i)     Rule 504 (b)(1)(ii)	Rule 505  Rule 506(b)  Rule 506(c)  Securities Act Section 4(a)(5)	
Rule 504(b)(1) (not (i), (ii)   or (iii))     Rule 504 (b)(1)(i)     Rule 504 (b)(1)(ii)     Rule 504 (b)(1)(iii)     Rule 504 (b)(1)(iiii)     Rule 504 (b)(1)(iiii)     Rule 504 (b)(1)(iiii)     Rule 504 (b)(1)(iiii)     Rule 504 (b)(1)(iiiii)     Rule 504 (b)(1)(iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii	Rule 505  Rule 506(b)  Rule 506(c)  Securities Act Section 4(a)(5)	
Rule 504(b)(1) (not (i), (ii)   or (iii))   Rule 504 (b)(1)(i)   Rule 504 (b)(1)(ii)   Rule 504 (b)(1)(iii)   Rule 504 (b)(1)(iiii)   Rule 504 (b)(1)(iiiii)   Rule 504 (b)(1)(iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii	Rule 505  Rule 506(b)  Rule 506(c)  Securities Act Section 4(a)(5)  Investment Company Act Section 3(c)	
Rule 504(b)(1) (not (i), (ii)   or (iii)	Rule 505  Rule 506(b)  Rule 506(c)  Securities Act Section 4(a)(5)  Investment Company Act Section 3(c)	
Rule 504(b)(1) (not (i), (ii)   or (iii))   Rule 504 (b)(1)(i)   Rule 504 (b)(1)(ii)   Rule 504 (b)(1)(iii)   Rule 504 (b)(1)(iiii)   Rule 504 (b)(1)(iiiii)   Rule 504 (b)(1)(iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii	Rule 505  Rule 506(b)  Rule 506(c)  Securities Act Section 4(a)(5)  Investment Company Act Section 3(c)	
Rule 504(b)(1) (not (i), (ii)   or (iii))   Rule 504 (b)(1)(i)   Rule 504 (b)(1)(ii)   Rule 504 (b)(1)(iii)   Rule 504 (b)(1)(iiii)   Rule 504 (b)(1)(iiiii)   Rule 504 (b)(1)(iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii	Rule 505  Rule 506(b)  Rule 506(c)  Securities Act Section 4(a)(5)  Investment Company Act Section 3(c)	
Rule 504(b)(1) (not (i), (ii)   or (iii))   Rule 504 (b)(1)(i)   Rule 504 (b)(1)(ii)   Rule 504 (b)(1)(iii)   Rule 504 (b)(1)(iiii)   Rule 504 (b)(1)(iiiii)   Rule 504 (b)(1)(iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii	Rule 505  Rule 506(b)  Rule 506(c)  Securities Act Section 4(a)(5)  Investment Company Act Section 3(c)	
apply)  Rule 504(b)(1) (not (i), (ii) or (iii))  Rule 504 (b)(1)(i)  Rule 504 (b)(1)(ii)  Rule 504 (b)(1)(iii)  ✓  Rule 504 (b)(1)(iii)  ✓  Amendment  Amendment	Rule 505  Rule 506(b)  Securities Act Section 4(a)(5)  Investment Company Act Section 3(c)  2018-11-30  First Sale Yet to Occur	
apply)  Rule 504(b)(1) (not (i), (ii) or (iii))  Rule 504 (b)(1)(i)  Rule 504 (b)(1)(ii)  Rule 504 (b)(1)(iii)  Rule 504 (b)(1)(iii)  Amendment  Rule 504 (b)(1)(iii)  Date of First Sale  Amendment	Rule 505  Rule 506(b)  Securities Act Section 4(a)(5)  Investment Company Act Section 3(c)  2018-11-30  First Sale Yet to Occur	
Rule 504(b)(1) (not (i), (ii) or (iii))	Rule 505  Rule 506(b)  Securities Act Section 4(a)(5)  Investment Company Act Section 3(c)  2018-11-30  First Sale Yet to Occur	
Rule 504(b)(1) (not (i), (ii) or (iii))	Rule 505  Rule 506(b)  Securities Act Section 4(a)(5)  Investment Company Act Section 3(c)  2018-11-30  First Sale Yet to Occur	
Rule 504(b)(1) (not (i), (ii) or (iii))	Rule 505  Rule 506(b)  Securities Act Section 4(a)(5)  Investment Company Act Section 3(c)  2018-11-30  First Sale Yet to Occur	

	Warrant or Other Right to Another Security	
Other Right to Acquire	describe)	
Security		
10. Business Combination Tra		
Is this offering being made in connection with a bus transaction, such as a merger, acquisition or exchan		No
Clarification of Response (if Necessary)		
11. Minimum Investment		
Minimum investment accepted from any outside	\$ 50000	USD
investor	\$ 50000	CSD
12. Sales Compensation		
Recipient	Recipient CRD Number	None None
None		
(Associated) Broker or Dealer   None	(Associated) Broker or Deal Number	er CRD None
Street Address 1	Street Address 2	
N/A		
City	State/Province/Country	ZIP/Postal Code
N/A State(s) of Solicitation	DELAWARE  Fermion (Non-US)	00000
State(s) of Solicitation All States	Foreign/Non-US	
CALIFORNIA		
NEW JERSEY		
NEW YORK		
VERMONT		
WISCONSIN		
13. Offering and Sales Amour	nts	
Total Offering Amount \$ 4500000	USD   Indefinite	
Total Amount Sold \$ 4500000  Total Remaining to be	USD	
Sold \$ 0	USD   Indefinite	
Clarification of Response (if Necessary)		
14. Investors		
TT. IIIVGSIOIS		
Select if securities in the offering have be	en or may be sold to persons who	
do not qualify as accredited investors, Number of such non-accredited investors offering		

Regardless of whether securities in the offering have been or may be sole	d
to persons who do not qualify as accredited investors, enter the total	
number of investors who already have invested in the offering:	

15			

### 15. Sales Commissions & Finders' Fees Expenses

Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions	\$ 0	USD	<b>Estimate</b>
Finders' Fees	\$ 0	USD	<b>Estimate</b>
Dasponsa (if Nagassa)	**)		

Clarification of Response (if Necessary)

Ш	
11	

#### 16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$ 0	USD	<b>Estimate</b>

# Clarification of Response (if Necessary)

#### Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

#### **Terms of Submission**

In submitting this notice, each Issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities
  described and undertaking to furnish them, upon written request, the information furnished to
  offerees.
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
LIXTE BIOTECHNOLOG HOLDINGS, INC.	Y /s/ John Kovach	John Kovach	Chief Executive Officer	2018-12-11